Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 in severe asthma with standard therapy
CTR20170586Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fevipiprant in asthma, sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20170586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170586.